GLP-1 Medications and Addiction: 15 Questions, Answered Honestly

No medication "cures" addiction. Addiction is a chronic condition involving genetic, neurological, psychological, and social factors. GLP-1 medications like semaglutide (Ozempic/Wegovy) have shown promise in reducing cravings for certain substances in early research, but this is not the same as curing addiction. Even the most effective existing addiction medications — buprenorphine for opioids, naltrexone for alcohol — manage the condition rather than cure it.

As of April 2026, no GLP-1 medication is FDA-approved for treating any substance use disorder or behavioral addiction. Semaglutide is approved for type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). Any use for addiction is off-label. Some clinicians are prescribing GLP-1 medications off-label when patients also qualify for the approved indications, but this is an individual clinical decision, not a guideline-supported practice.

Published research covers alcohol use disorder (one RCT, one Swedish registry study, multiple observational cohorts), tobacco/nicotine (one completed lab trial, observational data, multiple recruiting trials), opioid use disorder (one small RCT with liraglutide, large observational cohort), cannabis use disorder (one large observational cohort), and cocaine/stimulants (preclinical animal studies only). Reports of effects on gambling, compulsive shopping, and other behavioral patterns exist but are entirely anecdotal — no clinical or observational studies have been published.

Alcohol has the strongest evidence base of any substance. The Hendershot RCT (JAMA Psychiatry 2025) showed 40-50% reduction in heavy drinking days with semaglutide. The Lähteenvuo Swedish registry study (JAMA Psychiatry 2025) found 36% fewer alcohol-related hospitalizations across 228,000 patients. Multiple Wang/Volkow observational studies show 50-56% lower risk of developing or relapsing into AUD. This convergence of RCT, registry, and observational evidence is unusually robust for an off-label indication.

In the clinical trials, craving reductions were measurable within the first 1-2 weeks. The Penn State opioid trial showed effects beginning in week one. Anecdotal reports from people taking GLP-1 medications for weight loss often describe noticing reduced interest in alcohol or other substances within 2-4 weeks, typically as the dose titrates upward. However, individual responses vary widely, and some people report no change in addictive behavior at all.

There's no long-term data on this specific question for addiction. However, the weight management data provides a useful parallel: appetite and food cravings generally return when GLP-1 medications are discontinued, and weight regain is common. It's reasonable to expect that substance cravings would similarly return when the medication leaves the system. This is why behavioral therapy, support systems, and lifestyle changes remain essential — medications are tools, not substitutes for recovery work.

GLP-1 medications are not contraindicated with alcohol, but the combination may increase the risk of nausea, hypoglycemia (especially in diabetic patients), and gastrointestinal distress. A 2025 Virginia Tech study found that semaglutide may slow alcohol absorption, potentially altering how quickly alcohol affects you. If you're taking a GLP-1 medication and drinking, tell your prescriber — they need to know to manage your treatment safely.

GLP-1 medications do not produce euphoria, intoxication, or any subjective "high." They have no known abuse potential. In fact, the pharmacological mechanism is essentially the opposite of an abusable drug — rather than stimulating the reward pathway, they dampen it. The DEA does not classify GLP-1 medications as controlled substances.

Some patients report emotional blunting, reduced pleasure, or depressive symptoms on GLP-1 medications. This has biological plausibility — if the reward pathway is dampened broadly, it could reduce pleasure from positive experiences alongside reducing cravings. However, large-scale safety data (including a Wang/Volkow study specifically examining suicidal ideation risk) has not found increased rates of suicidality. If you experience mood changes on a GLP-1 medication, report them to your prescriber immediately.

There's no head-to-head comparison data. Semaglutide has the most published research (observational studies and the Hendershot alcohol RCT). Liraglutide has the only opioid craving RCT (Penn State). Tirzepatide (a dual GLP-1/GIP agonist) has early trials for both alcohol and methamphetamine but no published results yet. We genuinely don't know which molecule works best for which substance — that's a question for future research.

Since no GLP-1 is approved for addiction, you'd need to qualify for an approved indication — BMI ≥30, or BMI ≥27 with a weight-related comorbidity, or type 2 diabetes. Many people with substance use disorders do meet these criteria. The addiction research can be part of the clinical conversation, but it won't be the formal reason on the prescription. See our guide on talking to your doctor for practical advice.

Never stop FDA-approved addiction medications (buprenorphine, methadone, naltrexone, acamprosate, disulfiram, varenicline) without medical supervision. These medications have decades of evidence and save lives. The GLP-1 addiction research is preliminary. If anything, the early data (particularly the Penn State opioid trial) suggests GLP-1 medications might work alongside existing treatments, not as replacements.

Brand-name semaglutide (Ozempic/Wegovy) can cost over $1,000/month without insurance. Compounded semaglutide from telehealth providers typically runs $149-$299/month. Insurance coverage depends on your plan and diagnosis. Since addiction isn't an approved indication, insurance won't cover GLP-1 medications specifically for substance use disorder. We compare 20+ providers with verified pricing on our providers page.

Several large trials are expected to report in 2026-2027, including the NIAAA semaglutide-for-AUD trial, the UNC nicotine intake trial results, and the UT Houston smoking cessation trial. An Eli Lilly trial is also expected to read out. If these larger, longer trials confirm the preliminary findings, we could see FDA-indication expansion discussions beginning by 2028-2029 at the earliest. The research is moving fast by academic standards, but slow by the standards of people who need help now.

That's what this site is for. We track clinical trials, break down published studies, and maintain an honest assessment of where the evidence stands. No hype, no miracle claims — just data. Browse The Signal for our full archive, or start with our flagship article on the Hendershot alcohol trial.